Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway

Figure 4

Effect of hepatic ischemia reperfusion (HIR) alone or in combination with intraperitoneal administration of vildagliptin (Vilda) (10 mg/kg for 10 days) on quantification data (a) and protein expression of caspase-3 detected by Western blotting (b) in the hepatic tissues of experimental rat groups. Data were expressed as mean ± SD. ^aSignificant difference from the sham group at . ^bSignificant difference from the HIR group at .

(a)

(b)